Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | DRD4 | P21917 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTAFR | P25105 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9054931 | 0.99 | DRD2 (0.46) | DRD2DRD4TP53CYP1A2CYP3A4 | |
| SCHEMBL5953609 | 0.98 | DRD2 (0.48) | DRD2DRD4TP53CYP1A2CYP3A4 | |
| SCHEMBL5953188 | 0.87 | DRD2 (0.46) | DRD2DRD4TP53MAPTTDP1 | |
| SCHEMBL5953638 | 0.86 | DRD2 (0.62) | DRD2DRD4TP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9054094 | 0.86 | DRD2 (0.45) | DRD2DRD4TP53MAPTTDP1 | |
| SCHEMBL8892053 | 0.86 | SIGMAR1 (0.50) | DRD2DRD4LMNA | |
| SCHEMBL8894368 | 0.86 | DRD2 (0.45) | DRD2DRD4TP53CYP1A2CYP3A4 | |
| SCHEMBL5953744 | 0.84 | DRD2 (0.46) | DRD2DRD4TP53CYP1A2CYP3A4 | |
| SCHEMBL5953173 | 0.83 | DRD2 (0.46) | DRD2DRD4TP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9056544 | 0.83 | DRD2 (0.46) | DRD2DRD4TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | claimed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | claimed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | claimed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | claimed |
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | disclosed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | disclosed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | DBH, MAOB, AADAT | DRD2 28/4885DRD4 79/4885TP53 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.